Company Description

NovAb is focused on developing and commercializing a new class of monoclonal antibodies (“mAbs”) termed variable lymphocyte receptors (“VLRs”). VLRs are the antigen receptors utilized by the adaptive immune system of jawless vertebrates (lamprey and hagfish) comprise a single polypeptide structure with distinctive binding site geometry versus conventional mAbs.